It was previously shown that a tat mutant (tat 22 ) where cystreactivation of the latent infection in PBMCs from seroposieine 22 is substituted by glycine behaves as a transdomitive patients. The antiviral effect of tat 22 was limited to connant negative mutant in Jurkat T cells lytically or latently ditions of low virus production. The use of tat 22 may be infected by HIV-1. In this study we demonstrate that tat 22 promising for a gene therapy approach to AIDS during the controls HIV-1 replication in primary cells. This effect was asymptomatic phase of the disease allowing control of observed both after in vitro infection of peripheral blood virus replication in infected cells and inhibition of virus mononuclear cells (PBMCs) from normal donors and after spread to uninfected cells.
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Intracellular immunization for the acquired immune transcriptional activator of expression of all HIV-1 genes following specific interaction with the TAR sequence deficiency syndrome (AIDS) aims at control of replication of the human immunodeficiency virus (HIV) and spreadlocated at the 5′ end of all viral RNAs. 3 Tat is essential for viral replication, is important for transition from latent to ing of infection in order to prevent dysregulation and destruction of the immune system and progression of the productive infection 4, 5 and displays pleiotropic activities on cell functions by means of paracrine and autocrine disease. Clinical trials are ongoing to determine in vivo the activity of anti-HIV molecules that were previously mechanisms. 6 Functionally, the first exon is necessary for the transactivating activity of Tat. Four distinct regions shown to have antiviral function in vitro and to be nontoxic when expressed intracellularly, such as the Rev have been identified within the first 72 amino acids (aa) called N-terminal (aa 1-21), cysteine-rich (aa 22-37), core transdominant negative mutant M10 (RevM10), alone or in combination with an antisense molecule directed to the (aa [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] and basic (aa domains. 3 The cysteinerich region, responsible for the formation of intramolecuTat transactivation response element (TAR), a ribozyme that cleaves HIV-1 RNA, and intrabodies against Rev or lar disulfide bonds and for stabilization of the protein, represents its transactivation domain. The basic region Env. 1 The majority of these studies is under clinical evaluation; however, the results of the first trials with contains nuclear localization signals and the binding site for TAR. Tat-mediated stimulation of transcription also RevM10 have shown that expression of the Rev mutant prolongs the survival of circulating T lymphocytes, likely involves participation of Tat in the TFIID transcriptionelongation complex and direct interaction between Tat inhibiting virus replication and spreading of natural infection. 2 These results are encouraging and suggest that and cellular proteins. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Besides its function as a viral transactivator, Tat modulates cellular gene expression gene therapy approaches against HIV infection should be implemented regarding protocols for ex vivo activation and proliferation, both as intracellular and extracellular protein, playing a direct and indirect role in dysreguland expansion of the target cells, the choice of the delivery systems, and the identification of other effective viral ation of the immune system, neurodegenerative processes, reactivation of viral infections and development and cellular targets, in order to define the clinical protocols and improve the efficacy of this type of therapy.
of neoplasms during AIDS. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Several studies have shown that extracellular Tat stimulates growth of endoThe Tat protein of HIV-1 (86-102 amino acids), encoded by two exons early after infection, acts as a potent thelial cells activated by inflammatory cytokines and induces angiogenesis, invasion and proliferation of cells derived from Kaposi's sarcoma (KS), suggesting an active role of this protein in the development of KS, the most 
kb tat-transcript directed from the 5′ LTR. (d) Ethidium bromide staining of the agarose-formaldehyde gel before Northern blot analysis. Position of the 28S and 18S ribosomal RNAs is indicated in (c) and (d).
ticipate in the early events involved in the pathogenesis death early after infection. 36 Extracellular Tat has been found both in the supernatant medium of cultured cells 36 of B cell lymphomas frequently observed in HIV-1 seropositive patients. 42 In addition, it has been suggested that and in the serum 27 or in KS lesions of HIV-1 infected patients. 37 Extracellular Tat can be internalized, migrate Tat may play a role in HIV-1 virulence distinct from its trancriptional function and be a component of viral parto the nucleus and transactivate HIV-1 LTR 45 in cell lines containing an integrated LTR-CAT molecule. Moreover, ticles interacting with the TAR sequences of the two genomic RNA molecules and with structural viral prothe recent observation that Tat at picomolar concentrations induces activation of phosphatidylinositol 3-kinteins. 43, 44 Tat is secreted by the cells in the absence of cell to gly) in the transactivation domain, permanently rus was present in five P-Lt 22 clones (cl 1A, 2A, 3B, 3C and 3D), in the range of 1-2 ge per cell, whereas in clones 1B and 1D the integrated proviral DNA was not detectable (Figure 2b) . Bands of larger size were detected in Pase in uninfected cells without internalization suggests Ltat 22 cl 2A, 3C and 3D and in P-LX cl 1X and 9X, sugthat Tat can modulate cell activities through a second gesting additional integration of rearranged proviruses in messenger molecule. 46 Thus, inhibition of Tat functions these producer cell clones. Expression of LXSN and is a very promising therapeutic approach since it would Ltat 22 SN integrated proviruses was next analyzed by block HIV-1 gene expression and replication as well as Northern blotting. Hybridization of cytoplasmic RNAs the indirect pathogenic effects associated with this with a neo-specific probe showed expression of the protein.
We reported previously that a Tat mutant (tat 22 , cys 22 expected 2.8 and 1.5 kb mRNAs in P-LX cl 1X, 8X and 9X Values of CD4 and CD8 T lymphocytes (cell count/l), as well as p24 concentration in serum and diagnosis refer to the time of blood sampling for these experiments, during the period January-October 1996. ( Figures 1a and c) ; whereas RNA hybridization with a tatTo determine the antiviral effect of tat 22 in human peripheral blood cells from HIV-1 seronegative healthy specific probe showed the presence of the 3.2 kb tat-transcript in all seven P-Ltat 22 clones (Figures 2a and c) . Since donors infected in vitro, CD4 + T lymphocytes enriched cultures from each donor were stimulated with PHA and equal amounts of RNA were loaded into the gel (Figure  2d) , the different intensity in hybridization signals indi-IL-2, and transduced with control and tat 22 retroviral vectors by cocultivation with the P-LX cl 8X and P-Ltat 22 cl cated that tat 22 mRNA was expressed at the highest levels in P-Ltat 22 cl 3B. P-Ltat 22 cl 3B and P-LX cl 8X appeared 3B producer cell lines. Aliquots of the transduced cells were collected in order to control the presence and to be the best clones in terms of integration pattern and expression of the proviral recombinant DNA. Retrovirus expression of the integrated recombinant provirus by RT-PCR analysis and hybridization with a tat-specific probe production by these two clones was thus titrated on NIH3T3 cells and these cell lines were chosen as producer (Figure 3a) . The rest of the cultures were infected with HIV-1 (HXBC2 clone) at three different multiplicities of cell clones to transduce primary lymphocytes. infection. These experiments showed a 69% reduction in of HIV-1 replication seems to correlate with the viral load and be more effective at a low MOI or low virus pro-HIV-1 replication in tat 22 expressing cells when a ratio of 1:133 infectious particle (IP) per cell (Figure 3b ) or lower duction, both during in vitro and in vivo established infections. Interference by the Tat mutant with HIV-1 repli-(data not shown) were used, whereas at the higher ratio of 1:25 IP per cell lymphocytes were not protected against cation was indeed evident when a MOI of 1:133 IP per cell or lower were used to infect PBLs from healthy HIV-1 infection (not shown).
Figure 3 Transduction, selection and infection with HIV-1 of human

Figure 4 PCR analysis of tat22, neo and env sequences in PBLs from 12 HIV-1 infected patients transduced with the retroviral vectors Ltat22SN and LXSN. Patients were chosen mostly in the asymptomatic phase of infection as shown in
The effect of tat 22 on HIV-1 replication was next evaludonors, and in patients P5, P12 and P18 who were p24 seronegative at the time of blood sampling ( Table 2) and ated in cells infected in vivo. CD4 + T lymphocytes were purified from peripheral blood mononuclear cells of 12 whose CD4 + T lymphocytes released low levels of virus at day 5 after stimulation, as determined by the RT values HIV-1 seropositive donors. As shown in Table 2 , at the time of blood sampling seven patients were in the ( Figure 5 ). At present this anti-tat approach may be promising in the asymptomatic phase of the disease allowing asymptomatic phase of infection, had a CD4 + count ranging from 271 to 940 cells per microliter and, with the protection of the infected cells and control of virus spread to uninfected cells. We are currently exploring the possiexception of P4, P7 and P11, were p24 seronegative. Patients P9, P16 and P17 were affected with Candida bility that tat 22 may be effective at a higher viral load when it is expressed in a retroviral vector different from stomatitis, had a CD4 + T cell count ranging from 242 to 553 cells per microliter and were p24 seronegative.
LXSN, based on the observation that an effector molecule exerts different protection patterns against HIV-1 infecPatients P12 and P18 were diagnosed with lymphoadenopathy and anal Condyloma acuminatum, respectively. They tion depending on the vector backbone in which it is inserted. 49 Our results and those reported by others [50] [51] [52] [53] [54] both had a relatively high CD4 + T cell number (353 and 393 per microliter) and were p24 seronegative. CD4 + T suggest that, in the absence of a vaccine or a successful drug therapy, a gene therapy approach based on anti-tat lymphocytes enriched cultures were induced to proliferate with OKT3 monoclonal antibody and IL-2, and transmolecules could be effective to control HIV-1 infection.
To this purpose, the use of Tat transdominant negative duced by multiple infections with control and tat 22 -containing retroviral vector supernatants. Transduction of mutants in the cysteine region may be promising for several reasons. Tat 22 competes with wild-type Tat transthese cells with the recombinant retroviruses and infection by HIV-1 were assessed, respectively, by PCR ampliactivation activity on HIV-1 LTR driven gene expression and virus replication. Moreover, substitution of cys 22 to fication of tat 22 and neo sequences (Figure 4a and b) and env proviral sequences (Figure 4c) . Analysis of HIV-1 gly abolishes different Tat functions, such as (1) the direct interaction of Tat with the cellular kinase TAK in the virus released in the culture supernatants of the activated and transduced lymphocytes showed that tat 22 reduced transcription-initiation complex, leading to hyperphosphorylation of the carboxy-terminal domain of RNA polII virus production by 30.5, 87 and 99% in cell cultures derived from patients P5, P12 and P18, respectively, as and activation of transcription; 11 (2) the ability of Tat to up-regulate bcl-2 gene expression and to inhibit compared with cells from the same donors transduced with the control vector ( Figure 5 ). apoptosis; 55 and (3) the up-regulation of c-Fos induced by Tat, 56 supporting the possible use of Tat 22 to compete The results of these experiments show that tat 22 exerts an antiviral activity in human primary lymphocytes also with functions of wild-type Tat not related to viral replication. Considering that Tat 22 , as wild-type Tat, may infected both in vitro and in vivo. Tat 22 not only controls replication of laboratory HIV-1 isolates but is also effecbe secreted and internalized by the transduced cells and that it competes with the wild-type Tat protein, the use tive against virus strains that cause natural infection, since it interferes with reactivation of HIV-1 replication of Tat mutants in the transactivation domain may have the advantage of interfering both with intracellular and in infected lymphocytes from AIDS patients. Inhibition
